CNTB Stock Risk & Deep Value Analysis
Connect Biopharma Holdings Ltd
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CNTB Stock
We analyzed Connect Biopharma Holdings Ltd using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CNTB through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
CNTB Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Negative or inconclusive Phase 3 trial results for lead asset
- 📅
Significant dilutive capital raises impacting per-share value
- 📅
Increased competitive pressure from larger pharmaceutical companies
- 📅
Regulatory setbacks or delays in drug approval processes
Unlock CNTB Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Connect Biopharma Holdings Ltd (CNTB) Do?
Market Cap
$157.09M
Sector
Healthcare
Industry
Biotechnology
Employees
62
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States. The company's lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma. Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Visit Connect Biopharma Holdings Ltd WebsiteInvestment Thesis
Connect Biopharma is a speculative, high-risk, high-reward investment betting on the successful clinical development and commercialization of its lead immunology assets, particularly Rademikibart. With a clear focus on large therapeutic markets, positive analyst sentiment, and some pipeline execution (China NDA), the company offers substantial upside potential if it overcomes significant financial hurdles (dilution) and competitive pressures in the next 3-5 years.
Is CNTB Stock Undervalued?
Unlock the full AI analysis for CNTB
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
CNTB Price Targets & Strategy
12-Month Target
$8.67
Bull Case
$10.00
Bear Case
$1.00
Valuation Basis
Median analyst target of $8.67, reflecting anticipated pipeline success; traditional valuation metrics are not applicable for early-stage biotech.
Entry Strategy
Given the high-risk profile and market volatility, dollar-cost averaging in the current range of $2.50-$3.00 is advisable. Monitor for dips towards prior support levels, though specific technical levels are not provided by real-time intelligence.
Exit Strategy
Take profit on significant positive trial data announcements, regulatory milestones, or commercialization partnerships. Set a stop-loss order below recent lows, e.g., $2.00, to manage downside risk.
Portfolio Allocation
2-4% for aggressive risk tolerance; not suitable for conservative or moderate portfolios.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is CNTB Financially Healthy?
Valuation
P/E Ratio
-3.82
Price/Book
2.85
Price/Sales
206.01
Profitability
Return on Equity
-59.69%
EPS
$-0.30
Balance Sheet
Current Ratio
5.48
Quick Ratio
4.81
Debt/Equity
0.01
Cash & Equivalents
$54.80M
Other
Beta (Volatility)
-0.20
Does CNTB Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Stable (Potential to expand if lead assets achieve regulatory approval and significant market adoption)
Moat Sources
1 Identified
Currently very low; the durability of any moat is entirely dependent on the successful completion of clinical trials, regulatory approvals, and sustained efficacy against strong competition. Biotech moats are primarily driven by strong, novel intellectual property.
Moat Erosion Risks
- •Clinical trial failures or safety issues for lead drug candidates
- •Loss of patent protection or inability to secure new patents
- •Development of superior or more cost-effective treatments by competitors
- •Limited market adoption or reimbursement challenges post-approval
CNTB Competitive Moat Analysis
Sign up to see competitive advantages
CNTB Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (No specific data provided; assumes mixed sentiment typical of high-risk biotech)
Institutional Sentiment
Positive (Moderate Buy consensus with 5 ratings; high institutional ownership at ~58.7%)
Insider Activity (Form 4)
President David Leslie Szekeres and Director Karen J. Wilson filed initial ownership (Form 3) on March 16, 2026, holding 215,739 and 10,000 ordinary shares/options respectively. Director James A. Schoeneck holds options for 120,000 shares. No new insider buys or sells reported in the last 90 days (Dec 24, 2025 – Mar 24, 2026).
Options Flow
Normal options activity (No specific unusual options activity data provided)
Earnings Intelligence
Next Earnings
March 23, 2026 (Q4 2025 or FY 2025) - results likely already released or pending imminent release, market reaction potentially baked in or anticipated.
Surprise Probability
Medium (Consensus EPS estimate of -$1.72 indicates high burn, but any positive pipeline updates could lead to a 'surprise' sentiment shift regardless of financials)
Historical Earnings Pattern
No historical earnings reaction patterns provided; however, biotech stocks typically react strongly to pipeline news and cash runway updates rather than traditional profitability metrics.
Key Metrics to Watch
Competitive Position
Top Competitor
REGN (Regeneron Pharmaceuticals)
Market Share Trend
Currently none; aiming to gain market share upon successful commercialization of pipeline assets.
Valuation vs Peers
CNTB trades at a significant discount in market capitalization ($0.16B vs. $82B for Regeneron), reflecting its early-stage, pre-profitability status and higher risk profile. Direct valuation multiples like P/E are not comparable.
Competitive Advantages
- •Specific IL-4R/IL-13 targeting antibodies (Rademikibart) in clinical development
- •Proprietary drug pipeline in immunology
- •Early market access strategy for China via licensee
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive CNTB Stock Higher?
Near-Term (0-6 months)
- •Expected Q4 2025/FY 2025 Earnings (March 23, 2026 - *already passed* or imminent release)
- •Details from March 4, 2026 8-K current report (unspecified details)
- •Further updates on China NDA submission for Rademikibart (Phase 2)
Medium-Term (6-18 months)
- •Phase 3 trial results for lead pipeline asset (e.g., Rademikibart/Atozicitam) (mid-late 2026, as per previous analysis)
- •Announcement of a major commercialization partnership for global markets
- •Advancement of other pipeline candidates (CBP-201, CBP-307, CBP-174) into later stages
Long-Term (18+ months)
- •Regulatory approvals and market launch of lead assets in major global markets
- •Establishment of market leadership in specific immunology sub-segments
- •Expansion of pipeline into new therapeutic areas
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CNTB?
- ✓
Announcements of Phase 3 trial results for Rademikibart/Atozicitam
- ✓
New commercialization partnerships or significant non-dilutive funding
- ✓
Updates on cash runway and terms of any new equity raises
- ✓
Any shifts in analyst ratings or price targets
Bull Case Analysis
See what could go right with Premium
Competing with CNTB
See how Connect Biopharma Holdings Ltd compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Connect Biopharma Holdings Ltd CNTB | $157.1M | 4.3 | -3.8 | $10,000 | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Connect Biopharma Holdings Ltd (CNTB)?
As of March 24, 2026, Connect Biopharma Holdings Ltd has a DVR Score of 4.3 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Connect Biopharma Holdings Ltd?
Connect Biopharma Holdings Ltd's market capitalization is approximately $157.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Connect Biopharma Holdings Ltd use?
CNTB is the ticker symbol for Connect Biopharma Holdings Ltd. The company trades on the NGM.
What is the risk level for CNTB stock?
Our analysis rates Connect Biopharma Holdings Ltd's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of CNTB?
Connect Biopharma Holdings Ltd currently has a price-to-earnings (P/E) ratio of -3.8. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Connect Biopharma Holdings Ltd's revenue growing?
Connect Biopharma Holdings Ltd has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is CNTB stock profitable?
Connect Biopharma Holdings Ltd has a profit margin of 0.0%. The company is currently unprofitable.
How often is the CNTB DVR analysis updated?
Our AI-powered analysis of Connect Biopharma Holdings Ltd is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CNTB (Connect Biopharma Holdings Ltd) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.